| Outcome Measures: |
Primary: rongliflozin: area under the drug-time curve (AUC) ratios of geometric means of rongliflozin+rifampicin relative to rongliflozin alone., To assess the effect of rifampicin on the AUC of rongliflozin, from 0 hour（pre-dose,within 30mins）to 5 days after rongliflozin dosing|rongliflozin: The peak concentration (Cmax) ratios of geometric means of rongliflozin+rifampicin relative to rongliflozin alone., To assess the effect of rifampicin on the Cmax of rongliflozin, from 0 hour（pre-dose,within 30mins）to 5 days after rongliflozin dosing|rongliflozin: AUC ratios of geometric means of rongliflozin+probenecid relative to rongliflozin alone., To assess the effect of probenecid on the AUC of rongliflozin, from 0 hour（pre-dose,within 30mins）to 5 days after rongliflozin dosing|rongliflozin:Cmax ratios of geometric means of rongliflozin+probenecid relative to rongliflozin alone., To assess the effect of probenecid on the Cmax of rongliflozin, from 0 hour（pre-dose,within 30mins）to 5 days after rongliflozin dosing | Secondary: The time to peak (Tmax) of Rongliflozin., To assess the effect of rifampicin and probenecid on the Tmax of rongliflozin, from 0 hour（pre-dose,within 30mins）to 5 days after rongliflozin dosing|pharmacology (PD) of rongliflozin: cumulative urine glucose excretion every 24 hours, evaluate the cumulative urine glucose excretion every 24 hours after rongliflozin administration., from 0 hour to 5 days after rongliflozin dosing|the number of participants with adverse events (AE) in Cohort A, To evaluate the safety and tolerability of single dose of rongliflozin and combination of rifampin, from screening to 3 days after last dose of rifampicin|the number of participants with adverse events (AE) in Cohort B, To evaluate the safety and tolerability of single dose of rongliflozin and combination of probenecid, from screening to 3 days after last dose of probenecid
|
